ST. LOUIS--(BUSINESS WIRE)--Mediomics, LLC has been awarded an $185,000 Phase I SBIR contract (HHSN261201000040C) from the National Cancer Institute. The major goal of this project is to develop a hand-held biosensor and PINCER™-based assay reagents for in-process analysis of biologics production. This project will culminate with beta testing by a collaborating third-party manufacturer. Since 2007, Mediomics has received more than two million dollars of US government funding to develop its quick and sensitive homogenous PINCER™ protein assay.
